Dustin G. Shaw

Dustin G. Shaw

Auto-generated profile, based on publicly available information

Dustin G. Shaw

University of Chicago Department of Medicine, Section of Rheumatology 4 , Chicago, IL

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in Immunity
Verified
Journal Article
Closed access
JBJeffrey J. Bunker
Jeffrey J. Bunker
TFTheodore Flynn
Theodore Flynn
JKJason C. Koval
Jason C. Koval
DSDustin G. Shaw
Dustin G. Shaw
MMMarlies Meisel
Marlies Meisel
ABAlbert Bendelac
Albert Bendelac

1 February 2019 in Cell
Verified
Journal Article
Closed access
TMToufic Mayassi
Toufic Mayassi
KLKristin Ladell
Kristin Ladell
HGHerman Gudjonson
Herman Gudjonson
JMJames E. McLaren
James E. McLaren
DSDustin G. Shaw
Dustin G. Shaw
BJBana Jabri
Bana Jabri

1 January 2020 in The Lancet Infectious Diseases
Verified
Journal Article
Open access
DBDavid I Bernstein
David I Bernstein
JGJeffrey Guptill
Jeffrey Guptill
ANAbdollah Naficy
Abdollah Naficy
RNRaffael Nachbagauer
Raffael Nachbagauer
FBFrancesco Berlanda-Scorza
Francesco Berlanda-Scorza
Florian KrammerFlorian Krammer
Florian Krammer
Influenza viruses cause substantial annual morbidity and mortality globally. Current vaccines protect against influenza only when well matched to the circulating strains. However, antigenic drift can cause considerable mismatches between vaccine and circulating strains, substantially reducing vaccine effectiveness. Moreover, current seasonal vaccines are ineffective against pandemic influenza, and production of a vaccine matched to a newly emerging virus strain takes months. Therefore, there is an unmet medical need for a broadly protective influenza virus vaccine. We aimed to test the ability of chimeric H1 haemagglutinin-based universal influenza virus vaccine candidates to induce broadly cross-reactive antibodies targeting the stalk domain of group 1 haemagglutinin-expressing influenza viruses. We did a randomised, observer-blinded, phase 1 study in healthy adults in two centres in the USA. Participants were randomly assigned to one of three prime-boost, chimeric haemagglutinin-based vaccine regimens or one of two placebo groups. The vaccine regimens included a chimeric H8/1, intranasal, live-attenuated vaccine on day 1 followed by a non-adjuvanted, chimeric H5/1, intramuscular, inactivated vaccine on day 85; the same regimen but with the inactivated vaccine being adjuvanted with AS03; and an AS03-adjuvanted, chimeric H8/1, intramuscular, inactivated vaccine followed by an AS03-adjuvanted, chimeric H5/1, intramuscular, inactivated vaccine. In this planned interim analysis, the primary endpoints of reactogenicity and safety were assessed by blinded study group. We also assessed anti-H1 haemagglutinin stalk, anti-H2, anti-H9, and anti-H18 IgG antibody titres and plasmablast and memory B-cell responses in peripheral blood. This trial is registered with ClinicalTrials.gov, number NCT03300050. Between Oct 10, 2017, and Nov 27, 2017, 65 participants were enrolled and randomly assigned. The adjuvanted inactivated vaccine, but not the live-attenuated vaccine, induced a substantial serum IgG antibody response after the prime immunisation, with a seven times increase in anti-H1 stalk antibody titres on day 29. After boost immunisation, all vaccine regimens induced detectable anti-H1 stalk antibody (2·2-5·6 times induction over baseline), cross-reactive serum IgG antibody, and peripheral blood plasmablast responses. An unsolicited adverse event was reported for 29 (48%) of 61 participants. Solicited local adverse events were reported in 12 (48%) of 25 participants following prime vaccination with intramuscular study product or placebo, in 12 (33%) of 36 after prime immunisation with intranasal study product or placebo, and in 18 (32%) of 56 following booster doses of study product or placebo. Solicited systemic adverse events were reported in 14 (56%) of 25 after prime immunisation with intramuscular study product or placebo, in 22 (61%) of 36 after immunisation with intranasal study product or placebo, and in 21 (38%) of 56 after booster doses of study product or placebo. Disaggregated safety data were not available at the time of this interim analysis. The tested chimeric haemagglutinin-based, universal influenza virus vaccine regimens elicited cross-reactive serum IgG antibodies that targeted the conserved haemagglutinin stalk domain. This is the first proof-of-principle study to show that high anti-stalk titres can be induced by a rationally designed vaccine in humans and opens up avenues for further development of universal influenza virus vaccines. On the basis of the blinded study group, the vaccine regimens were tolerable and no safety concerns were observed. Bill & Melinda Gates Foundation.

12 October 2023 in Nature Methods
Verified
Journal Article
Closed access
PDF file
NWNatalie J. Wu-Woods
Natalie J. Wu-Woods
JBJacob T. Barlow
Jacob T. Barlow
FTFlorian Trigodet
Florian Trigodet
DSDustin G. Shaw
Dustin G. Shaw
ARAnna E. Romano
Anna E. Romano
RIRustem F. Ismagilov
Rustem F. Ismagilov

19 November 2018 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
KNKarlynn E. Neu
Karlynn E. Neu
JGJenna J. Guthmiller
Jenna J. Guthmiller
MHMin Huang
Min Huang
JLJennifer La
Jennifer La
MVMarcos C. Vieira
Marcos C. Vieira
PWPatrick Wilson
Patrick Wilson
Vaccines are among the most effective public health tools for combating certain infectious diseases such as influenza. The role of the humoral immune system in vaccine-induced protection is widely appreciated; however, our understanding of how antibody specificities relate to B cell function remains limited due to the complexity of polyclonal antibody responses. To address this, we developed the Spec-seq framework, which allows for simultaneous monoclonal antibody (mAb) characterization and transcriptional profiling from the same single cell. Here, we present the first application of the Spec-seq framework, which we applied to human plasmablasts after influenza vaccination in order to characterize transcriptional differences governed by B cell receptor (BCR) isotype and vaccine reactivity. Our analysis did not find evidence of long-term transcriptional specialization between plasmablasts of different isotypes. However, we did find enhanced transcriptional similarity between clonally related B cells, as well as distinct transcriptional signatures ascribed by BCR vaccine recognition. These data suggest IgG and IgA vaccine–positive plasmablasts are largely similar, whereas IgA vaccine–negative cells appear to be transcriptionally distinct from conventional, terminally differentiated, antigen-induced peripheral blood plasmablasts.

9 October 2025 in Journal of Experimental Medicine
Verified
Journal Article
Open access
SCSiriruk Changrob
Siriruk Changrob
AYAtsuhiro Yasuhara
Atsuhiro Yasuhara
SPSuncheol Park
Suncheol Park
SBSandhya Bangaru
Sandhya Bangaru
LLLei Li
Lei Li
PWPatrick Wilson
Patrick Wilson
The S2 subunit of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike is highly conserved across coronavirus strains and therefore is a potential pan-coronavirus vaccine target. However, antibodies targeting this region are typically non-neutralizing. We report herein that S2-targeting antibodies from patients who recovered from SARS-CoV-2 infection bound only closely related sarbecovirus subgenus strains and, like most known S2 antibodies, none of these were neutralizing. In contrast, first-exposure, severe acutely infected COVID-19 patients predominantly induced back-boosted antibody-secreting cells imprinted against past common cold coronavirus strain OC43 that were cross-reactive to as many as five subgenera of betacoronavirus strains and gave rise to antibodies that were neutralizing and protective. The antibodies targeted two different sites: one defined by competition with stem helix antibodies, and the second to an underdescribed epitope at the apex of S2. These findings suggest that S2-targeted vaccines could strategically exploit controlled OC43 priming followed by SARS-CoV-2 boosting to enhance the breadth and quality of protective antibody responses.